Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

PaxMedica progresses on African Sleeping Sickness treatment, eyes 2024 NDA submission

Published 10/11/2023, 17:08
© Reuters.
PXMD
-

In a significant update for PaxMedica, Chief Medical Officer David Hough highlighted the company's recent advancements in treating Human African Trypanosomiasis, commonly known as African Sleeping Sickness, during his appearance on The Bell2Bell podcast today. The discussion revolved around the promising outcomes from PaxMedica's PAX-HAT 301 study and other nonclinical programs that have recently been presented to the FDA.

PaxMedica, a biopharmaceutical company focusing on the development of anti-purinergic therapies for neurological disorders, has made substantial progress in its research efforts. Their leading drug candidate, PAX-101, an intravenous suramin formulation, is at the forefront of their work to address conditions such as autism spectrum disorder and African Sleeping Sickness. The FDA's recognition of PaxMedica's comprehensive nonclinical program marks a pivotal moment for the company as it moves closer to a potential treatment for this neglected tropical disease.

The Bell2Bell podcast, produced by InvestorBrandNetwork (IBN), offered a platform for PaxMedica to share these updates. IBN is known for its extensive experience in communications over 17 years and has amassed millions of followers across social media platforms. For further information about PaxMedica's advancements and other news, individuals can access the company's newsroom at PXMD.

The commitment of PaxMedica to combat neglected tropical diseases is further emphasized by their anticipated New Drug Application (NDA) submission slated for 2024. As the company continues its research initiatives focused on meeting the needs of patients with these conditions, this milestone represents a beacon of hope for those affected by African Sleeping Sickness.

InvestorBrandNetwork operates out of Los Angeles with a Corporate Communications department dedicated to client engagement and can be contacted for inquiries.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.